Tag: IN.PACT
Paclitaxel DCB performs well in ‘challenging anatomy’ of femoropopliteal in-stent restenosis,...
The IN.PACT Admiral drug-coated balloon (DCB) shows promising results in treating femoropopliteal in-stent restenosis (ISR) in a Society for Vascular Surgery (SVS) Vascular Quality...
New analysis: Four multicenter trials support primary use of drug-coated balloons...
A patient-level, propensity-adjusted comparison of three-year results from a quartet of prospective, multicenter trials support the primary use of drug-coated balloons (DCBs) versus bare...
Medtronic gains FDA nod for IN.PACT 018 DCB
Medtronic has announced approval from the Food and Drug Administration (FDA) for the IN.PACT 018 paclitaxel-coated percutaneous transluminal angioplasty (PTA) balloon catheter, a drug-coated...
New sirolimus data provide encouragement despite ‘potentially disappointing’ efficacy results
The results of a small-scale pilot study from Asia have indicated “potentially disappointing” results with a novel drug-eluting balloon in treating dysfunctional arteriovenous access...
CX 2022: IN.PACT AV DCB shows sustained and superior performance compared...
New randomized controlled data demonstrating the sustained and superior performance of IN.PACT AV drug-coated balloons (DCBs) compared to percutaneous transluminal angioplasty (PTA) through 36...
Medtronic issues voluntary recall for subset of IN.PACT Admiral and IN.PACT...
Medtronic recently voluntarily recalled a subset of its IN.PACT Admiral and IN.PACT AV paclitaxel-coated percutaneous transluminal angioplasty (PTA) balloon catheters due to the potential...
VIVA 2021: IN.PACT Admiral DCB found to provide ‘high five-year freedom...
Real-world data drawn from the IN.PACT Global study looking at five-year freedom from clinically driven target lesion revascularization (TLR) among prespecified chronic total occlusion...
European launch: Medtronic receives CE mark for 200mm and 250mm IN.PACT...
Medtronic has announced the European launch of the 200mm and 250mm IN.PACT Admiral drug-coated balloons (DCBs) following CE mark approval. The product is intended to treat long...
IN.PACT Admiral DCB shows ‘significant advantage’ over uncoated devices in fempop...
The IN.PACT Admiral drug-coated balloon (DCB) demonstrated a significant advantage in overall survival, amputation-free survival and target-lesion revascularization after femoropopliteal artery treatment through four-year...
Six-month IN.PACT AV Access results show superiority of DCB angioplasty
Just-published six-month results of the IN.PACT AV Access study show that drug-coated balloon (DCB) angioplasty is superior to standard angioplasty for the treatment of...
SVS acknowledges industry partners springing to aid of vascular community
It has recently come to the attention of the Society for Vascular Surgery (SVS) that many of our industry partners are generously donating equipment...
TOBA III clinical trial results published
Intact Vascular has announced the peer-reviewed publication of its Tack optimized balloon angioplasty (TOBA) III 12-month clinical trial results in the Journal of Vascular Surgery.
The multi-center, single-arm,...